



Immunotherapy against Myeloma

Guest Editors:

Dr. Monia Marchetti

Hematology Department,
University Hospital SS Antonio e
Biagio & Cesare Arrigo,
Alessandria, Italy

Dr. Federico Monaco

Azienda Ospedaliera Nazionale
Santi Antonio e Biagio e Cesare
Arrigo, Alessandria, Italy

Deadline for manuscript
submissions:
closed (31 December 2022)

Message from the Guest Editors

Dear Colleagues,

Mono- and bi-specific monoclonal antibodies and CAR-T are a mainstay of a new anti-myeloma era. Since the availability of several competing association therapies has caused therapeutic algorithms to rapidly evolve, the final scope of this Issue is to settle the hurdles to the widespread adoption of immunotherapies for multiple myeloma. This Special Issue will also host the debate on modern clinical endpoints for clinical trials and drug approval in the myeloma field.

Dr. Monia Marchetti
Dr. Federico Monaco
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)